Results 71 to 80 of about 3,569 (208)

Is vitamin D deficiency a risk factor for obesity-related morbidity, prediabetes, and type 2 diabetes — a literature review and proposals from the experts of the Polish Society of Endocrinology

open access: yesEndokrynologia Polska
Through pleiotropic effects related to the presence of its receptors in major human organs, vitamin D (VD) plays an important role in systemic homeostasis, especially in the proper functioning of muscles and bones.
Andrzej Milewicz   +5 more
doaj   +1 more source

Beyond Nutritional Deficiency: Persistent Rickets as a Manifestation of Vitamin D‐Dependent Rickets Type II in a Toddler

open access: yesClinical Case Reports, Volume 13, Issue 12, December 2025.
ABSTRACT Vitamin D‐dependent rickets type II (VDDR‐II) is a rare hereditary disorder caused by mutations in the vitamin D receptor gene, resulting in resistance to active vitamin D and impaired calcium absorption. We report a 2‐year and 6‐month‐old female toddler presenting with persistent rickets, delayed motor milestones, dental abnormalities, and ...
Abhisek Jha   +8 more
wiley   +1 more source

Stress fracture of the distal tibial metaepiphysis as a rare complication of interlocking intramedullary nailing

open access: yesГений oртопедии, 2020
Introduction This article describes a clinical case of a stress fracture of the distal tibial metaepiphysis following a high-energy tibial shaft fracture stabilized with interlocking intramedullary (IM) nail to identify an underlying cause of the ...
Mikhail S. Krivorotko   +2 more
doaj   +1 more source

Repurposing Acebutolol for Osteoporosis Treatment: Insights From Multi‐Omics and Multi‐Modal Data Analysis

open access: yesClinical Pharmacology &Therapeutics, Volume 118, Issue 6, Page 1463-1476, December 2025.
Overview of a multi‐omics based drug repurposing strategy. The systematic drug repurposing strategy included the following steps: (1) osteoporosis driver signaling networks were identified from multi‐omics data; (2) drug functional modules were obtained using a network fusion approach to integrate drug similarity information; (3) all drugs were ranked ...
Dan‐Yang Liu   +21 more
wiley   +1 more source

No difference between alfacalcidol and paricalcitol in the treatment of secondary hyperparathyroidism in hemodialysis patients: a randomized crossover trial

open access: yes, 2011
Alfacalcidol and paricalcitol are vitamin D analogs used for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease, but have known dose-dependent side effects that cause hypercalcemia and hyperphosphatemia.
Madsen, Jens   +27 more
core   +1 more source

A Health Technology Assessment Based on Chinese Guideline: Active Vitamin D and Its Analogs in the Treatment of Osteoporosis

open access: yesDrug Design, Development and Therapy
Siyong Huang, Jiabao Li, Xiao Hu, Jisheng Chen Key Specialty of Clinical Pharmacy, The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, People’s Republic of ChinaCorrespondence: Jisheng Chen, Key Specialty of Clinical Pharmacy,
Huang S, Li J, Hu X, Chen J
doaj  

Alendronate improves QOL of postmenopausal women with osteoporosis

open access: yesClinical Interventions in Aging, 2010
Hisaya Kawate1, Keizo Ohnaka2, Masahiro Adachi1, Suminori Kono3, Hideyuki Ikematsu4, Hisashi Matsuo5, Kazumi Higuchi6, Takehiko Takayama7, Ryoichi Takayanagi11Department of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu ...
Hisaya Kawate   +3 more
doaj  

Changes in fibroblast growth factor 23 during treatment of secondary hyperparathyroidism with alfacalcidol or paricalcitol

open access: yes, 2011
Background. Fibroblast growth factor 23 (FGF23) increases renal phosphate excretion and decreases the formation of 1,25 dihydroxyvitamin D. In patients with chronic kidney disease, plasma FGF23 levels are markedly elevated by unknown mechanisms.
L. Brandi   +14 more
core   +1 more source

Three-year experience with combined treatment with alendronate and alfacalcidol in Japanese patients with severe bone loss and osteoporotic fracture

open access: yesTherapeutics and Clinical Risk Management, 2011
Jun Iwamoto1, Yoshihiro Sato2, Mitsuyoshi Uzawa3, Tsuyoshi Takeda1, Hideo Matsumoto11Institute for Integrated Sports Medicine, Keio University School of Medicine, Tokyo, Japan; 2Department of Neurology, Mitate Hospital, Fukuoka, Japan; 3Department of ...
Iwamoto J   +4 more
doaj  

Alfacalcidol in clinical practice: focus on the efficacy and safety of the Russian generic drug

open access: yesСовременная ревматология
The most important factors that determine the risk of fractures are not only the presence of osteoporosis (OP), but also the risk of falls. In addition to sufficient physical activity, medications are needed that have a positive effect on the strength ...
N. V. Toroptsova   +2 more
doaj   +1 more source

Home - About - Disclaimer - Privacy